These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 35093868)

  • 1. CHFR-Promoter-Methylation Status Is Predictive of Response to Irinotecan-based Systemic Chemotherapy in Advanced Colorectal Cancer.
    Hagiwara T; Sugimoto K; Momose H; Irie T; Honjo K; Okazawa YU; Kawai M; Kawano S; Munakata S; Takahashi M; Kojima Y; Serizawa N; Nagahara A; Hoffman RM; Brock MV; Sakamoto K
    Anticancer Res; 2022 Feb; 42(2):697-707. PubMed ID: 35093868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of CHFR Promoter Methylation with Treatment Outcomes of Irinotecan-Based Chemotherapy in Metastatic Colorectal Cancer.
    Cha Y; Kim SY; Yeo HY; Baek JY; Choi MK; Jung KH; Dong SM; Chang HJ
    Neoplasia; 2019 Jan; 21(1):146-155. PubMed ID: 30562637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase 2 trial of gemcitabine and docetaxel in patients with metastatic colorectal adenocarcinoma with methylated checkpoint with forkhead and ring finger domain promoter and/or microsatellite instability phenotype.
    Baretti M; Karunasena E; Zahurak M; Walker R; Zhao Y; Pisanic TR; Wang TH; Greten TF; Duffy AG; Gootjes E; Meijer G; Verheul HMW; Ahuja N; Herman JG; Azad NS
    Clin Transl Sci; 2021 May; 14(3):954-963. PubMed ID: 33811727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CHFR silencing or microsatellite instability is associated with increased antitumor activity of docetaxel or gemcitabine in colorectal cancer.
    Pelosof L; Yerram SR; Ahuja N; Delmas A; Danilova L; Herman JG; Azad NS
    Int J Cancer; 2014 Feb; 134(3):596-605. PubMed ID: 23873170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Methylation-independent CHFR expression is a potential biomarker affecting prognosis in acute myeloid leukemia.
    Zhou JD; Zhang TJ; Li XX; Ma JC; Guo H; Wen XM; Yao DM; Zhang W; Lin J; Qian J
    J Cell Physiol; 2018 Jun; 233(6):4707-4714. PubMed ID: 29115660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Promoter methylation of CHFR gene in gastric carcinoma tissues detected using two methods.
    Cheng ZD; Hu SL; Sun YB; Xu WP; Shen G; Kong XY
    Chin J Cancer; 2010 Feb; 29(2):163-6. PubMed ID: 20109344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Checkpoint with forkhead-associated and ring finger promoter hypermethylation correlates with microsatellite instability in gastric cancer.
    Oki E; Zhao Y; Yoshida R; Masuda T; Ando K; Sugiyama M; Tokunaga E; Morita M; Kakeji Y; Maehara Y
    World J Gastroenterol; 2009 May; 15(20):2520-5. PubMed ID: 19469003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CHFR protein expression predicts outcomes to taxane-based first line therapy in metastatic NSCLC.
    Pillai RN; Brodie SA; Sica GL; Shaojin Y; Li G; Nickleach DC; Yuan L; Varma VA; Bonta D; Herman JG; Brock MV; Ribeiro MJ; Ramalingam SS; Owonikoko TK; Khuri FR; Brandes JC
    Clin Cancer Res; 2013 Mar; 19(6):1603-11. PubMed ID: 23386692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive value of CHFR and MLH1 methylation in human gastric cancer.
    Li Y; Yang Y; Lu Y; Herman JG; Brock MV; Zhao P; Guo M
    Gastric Cancer; 2015 Apr; 18(2):280-7. PubMed ID: 24748501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer.
    Overman MJ; Adam L; Raghav K; Wang J; Kee B; Fogelman D; Eng C; Vilar E; Shroff R; Dasari A; Wolff R; Morris J; Karunasena E; Pisanic TR; Azad N; Kopetz S
    Ann Oncol; 2018 Jan; 29(1):139-144. PubMed ID: 29069279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methylation of gene CHFR promoter in acute leukemia cells.
    Gong H; Liu W; Zhou J; Xu H
    J Huazhong Univ Sci Technolog Med Sci; 2005; 25(3):240-2. PubMed ID: 16201259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging evidence for CHFR as a cancer biomarker: from tumor biology to precision medicine.
    Derks S; Cleven AH; Melotte V; Smits KM; Brandes JC; Azad N; van Criekinge W; de Bruïne AP; Herman JG; van Engeland M
    Cancer Metastasis Rev; 2014 Mar; 33(1):161-71. PubMed ID: 24375389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Promoter hypermethylation of the Chfr gene in neoplastic and non-neoplastic gastric epithelia.
    Honda T; Tamura G; Waki T; Kawata S; Nishizuka S; Motoyama T
    Br J Cancer; 2004 May; 90(10):2013-6. PubMed ID: 15138487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CHFR promoter hypermethylation and reduced CHFR mRNA expression in ovarian cancer.
    Gao Y; Lou G; Zhang GM; Sun XW; Ma YY; Yang YM; Liu G
    Int J Biol Markers; 2009; 24(2):83-9. PubMed ID: 19634111
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aberrant promoter hypermethylation of the CHFR gene in oral squamous cell carcinomas.
    Baba S; Hara A; Kato K; Long NK; Hatano Y; Kimura M; Okano Y; Yamada Y; Shibata T
    Oncol Rep; 2009 Nov; 22(5):1173-9. PubMed ID: 19787237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanism and pathobiologic implications of CHFR promoter methylation in gastric carcinoma.
    Gao YJ; Xin Y; Zhang JJ; Zhou J
    World J Gastroenterol; 2008 Aug; 14(32):5000-7. PubMed ID: 18763281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aberrant methylation of the CHFR gene is frequently detected in non-invasive colorectal cancer.
    Morioka Y; Hibi K; Sakai M; Koike M; Fujiwara M; Kodera Y; Ito K; Nakao A
    Anticancer Res; 2006; 26(6B):4267-70. PubMed ID: 17201143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alternative efficacy-predicting markers for paclitaxel instead of CHFR in non-small-cell lung cancer.
    Takeshita M; Koga T; Takayama K; Yano T; Maehara Y; Nakanishi Y; Sueishi K
    Cancer Biol Ther; 2010 Nov; 10(9):933-41. PubMed ID: 20855974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epigenetic and genetic silencing of CHFR in esophageal adenocarcinomas.
    Soutto M; Peng D; Razvi M; Ruemmele P; Hartmann A; Roessner A; Schneider-Stock R; El-Rifai W
    Cancer; 2010 Sep; 116(17):4033-42. PubMed ID: 20564104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathobiologic implications of methylation and expression status of Runx3 and CHFR genes in gastric cancer.
    Hu SL; Huang DB; Sun YB; Wu L; Xu WP; Yin S; Chen J; Jiang XD; Shen G
    Med Oncol; 2011 Jun; 28(2):447-54. PubMed ID: 20300977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.